Clinical Trial Update: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of Capivasertib in relapsed or refractory B-cell non-Hodgkin lymphoma has completed, with results posted in June 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Capivasertib (capivasertib)

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-20